Virology · 2021 · 47 citations · 16 references
MedicineInfectious DiseasesPharmacologyDrug DiscoveryMolecular VirologyVirologyAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyViral InfectionsViral StructureAntiviral Structure-activity RelationshipsAntiviral TherapeuticsBroad-spectrum Antiviral AgentsRna-dependent Rna Polymerase FunctionSars-cov-2 InfectionTreatment Of Coronavirus InfectionsViral Polymerase InhibitorsViral Replication Inhibitors
Endemic seasonal coronaviruses cause morbidity and mortality in a subset of patients, but no specific treatment is available. Molnupiravir is a promising pipeline antiviral drug for treating SARS-CoV-2 infection potentially by targeting RNA-dependent RNA polymerase (RdRp). This study aims to evaluate the potential of repurposing molnupiravir for treating seasonal human coronavirus (HCoV) infections. Molecular docking revealed that the active form of molnupiravir, β-D-N4-hydroxycytidine (NHC), has similar binding affinity to RdRp of SARS-CoV-2 and seasonal HCoV-NL63, HCoV-OC43 and HCoV-229E. In cell culture models, treatment of molnupiravir effectively inhibited viral replication and production of infectious viruses of the three seasonal coronaviruses. A time-of-drug-addition experiment indicates the specificity of molnupiravir in inhibiting viral components. Furthermore, combining molnupiravir with the protease inhibitor GC376 resulted in enhanced antiviral activity. Our findings highlight the great potential of repurposing molnupiravir for treating seasonal coronavirus infected patients.
16
Identification of a new human coronavirus
Lia van der Hoek, Krzysztof Pyrć, Maarten F. Jebbink et al. · Nature Medicine · 2004 · 1.9K citations · Full text
Timothy P. Sheahan, Amy Sims, Shuntai Zhou et al. · Science Translational Medicine · 2020 · 1.2K citations · Full text
Heike Hofmann, Krzysztof Pyrć, Lia van der Hoek et al. · Proceedings of the National Academy of Sciences · 2005 · 890 citations · Full text